Close Menu

BioMérieux

Researchers from the diagnostics company will work with researchers from the microbial genomics lab of George Weinstock.

The firm's approach to sepsis is at the core of its infectious disease testing strategy with MDx, biomarker tests, and mass spec technologies all playing a role.

Despite the array of tests available, some lab directors are still seeking broader functionalities and capabilities from the systems they purchase.  

Molecular biology sales rose 38 percent, driven by €52 million in Q2 sales of the firm's FilmArray molecular diagnostic products.

The additions comprise 297 new species, including Mycobacterium tuberculosis, 45 species of non-tuberculous mycobacteria, and 48 medically important molds.

The recent approvals underscore the usefulness of procalcitonin as a sepsis biomarker, even as newer molecular approaches to diagnosing the condition hit the market.

The study involved 11 sites and 1,560 prospectively collected patient samples and demonstrated high overall positive and negative percent agreement with comparator assays.

On an organic basis, Q1 revenues grew more than 11 percent, driven in part by strong sales of its FilmArray, Vidas, and Vitek product portfolios.

The high-throughput system is now approved with the firm's Blood Culture ID, Gastrointestinal, Meningitis/Encephalitis, and the previously approved Respiratory Panel. 

Pages